Investigating the effects of chlorogenic acid on novel object recognition memory impairment, hyperlocomotion, and prefrontal BDNF expression in a sub-chronic ketamine-induced schizophrenia-like rat model Authors: Anahita Bahrami, Batool Ghorbani Yekta, Anita Baghdasarians Published: 2026 ABSTRACT AbstractSchizophrenia is a severe neuropsychiatric disorder characterized by positive, negative, cognitive, mood-related, and motor symptoms. Sub-chronic ketamine administration is widely used to induce schizophrenia-like behavioral and cognitive alterations in rodents. Chlorogenic acid (CGA) is an abundant dietary phenolic acid with reported anti-inflammatory, antioxidative, and neuroprotective properties. The present study examined the effects of CGA on behavioral disturbances in male and female rats exposed to sub-chronic ketamine administration, together with brain-derived neurotrophic factor (BDNF) expression in the prefrontal cortex. Ketamine was injected for 7 consecutive days (30 mg/kg, i.p.), and CGA was orally administered once (150 mg/kg) 24 h after the last ketamine injection. Ketamine increased locomotor activity in both sexes, with a greater effect in females; CGA partially reduced this effect only in males. Rearing was reduced only in ketamine-treated males, and CGA did not reverse this change. Grooming was increased in both sexes after ketamine administration, whereas CGA attenuated this effect only in females. Novel object recognition memory was impaired in both sexes after ketamine administration, and CGA partially attenuated this impairment. Immobility in the forced swim test was reduced only in ketamine-treated females, and CGA attenuated this effect. Prefrontal BDNF expression was decreased after ketamine administration in both sexes, and CGA partially attenuated this reduction. Overall, CGA showed partial and sex-dependent protective effects against selected ketamine-induced behavioral and molecular alterations. These findings should be interpreted in light of the absence of independent DMSO-only vehicle-control cohorts.Keywords: Schizophrenia, Ketamine, Chlorogenic acid (CGA), Sex differences, Brain-derived neurotrophic factor (BDNF) Introduction Schizophrenia is a severe neuropsychiatric disorder with positive, negative, and cognitive symptoms. Schizophrenia as a multi-dimensional disorder with a wide range of psychotic, negative, cognitive, mood, and motor dysfunctions (Tandon et al., 2024), has an overall prevalence of 5.03 per 1000 population (Bargagli et al., 2024). Preclinical models of schizophrenia often use sub-chronic ketamine administration to induce schizophrenia-like model. For example, ketamine at the dose of 30 mg/kg for five consecutive days leads to the induction of schizophrenia-like model in male Wistar rats, showing hyperlocomotion, novel object memory deficit, and decreased pain threshold, although sex differences have been also shown (Samizadeh et al., 2024). The other study that uses the same protocol showed hyperlocomotion, novel object memory deficit, and decreased pain threshold with sex differences (Manooki et al., 2025). Other protocols use ketamine administration at the dose of 25 mg/kg and for 5–8 consecutive days (Tekin et al., 2022, Canever et al., 2021). Elevated locomotion and disrupted working memory are among the most deleterious effects of sub-chronic administration of ketamine in rodents (Samizadeh et al., 2024, Tekin et al., 2022, Ahmed et al., 2018). Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor that is affected in rodent models of schizophrenia. BDNF modulates neurotransmission, neuroplasticity, neurogenesis, and cognitive functions and the mood state. Evidence has shown the relationship between BDNF abnormalities and psychiatric disorders and cognitive disturbances in clinical and preclinical models (Zou et al., 2024, Di Carlo et al., 2019, Motamedi-Manesh et al., 2025a, Ghaffarzadegan et al., 2024, Green et al., 2013, Shamabadi et al., 2025, Hauck et al., 2010). In rodent model of schizophrenia induced by ketamine, many studies have shown BDNF changes. Our recent works have revealed reduced BDNF levels in the prefrontal cortex of rats exposed to sub-chronic administration of ketamine (Samizadeh et al., 2024, Manooki et al., 2025). Other study has shown BDNF downregulation in the hippocampus and the medial prefrontal cortex of rats received ketamine (Gholizadeh et al., 2023). As mentioned, BDNF and other neurotrophins are involved in the growth and survival of neurons, and neurogenesis and synaptic plasticity. In the period of the brain development, different neurotrophic factors, particularly BDNF, potently promote neural growth and survival (Goren, 2016). Also, axonal and dendrite growth, neurogenesis, neuroplasticity, and synaptic connections depend on neurotrophic factors (especially BDNF) function (Goren, 2016, Favalli et al., 2012). Importantly, BDNF is crucial for the function of dopaminergic, cholinergic, and serotonergic signaling, that are critically implicated in cognitive disturbances in schizophrenia (Nieto et al., 2013, Angelucci et al., 2005). Of note, models of drug-induced psychosis have shown that reduced BDNF concentration is associated with the induction of psychotic symptoms (Ashe et al., 2002, Mattson, 2008, Lin and Huang, 2020). Therefore, abnormalities in the function and the level of BDNF may underlie the pathophysiology of schizophrenia. On the other hand, Chlorogenic acid (CGA) may show neuroprotective effects. CGA family members are abundant dietary phenolic acid compounds in plants and have multiple protective effects such as anti-inflammation, antioxidation, and metabolic homeostasis modulation (Nguyen et al., 2024, Xue et al., 2023, Stalmach et al., 2010). CGA crosses the blood-brain barrier and induces neuroprotective effects in the brain (Lee et al., 2012). CGA via induction of antioxidant and antiapoptotic properties can ameliorate cognitive impairments and improves mood disturbances (Bouayed et al., 2007, Han et al., 2010, Miyazaki et al., 2020). CGA also induces neuroprotective effects and improves learning and memory impairments (Kumar et al., 2019, Tajik et al., 2017). The anti-anxiety and antidepressant effects of CGA have also been declared in previous research (Bouayed et al., 2007, Wu et al., 2016, Song et al., 2019). CGA can suppress glutamate dehydrogenase (GDH) enzyme activity, the enzyme that is overactivated in schizophrenia (Domith et al., 2018). However, there is no clear evidence in this regard. CGA serves as a neuroprotective agent via increasing the availability of BDNF in the frontal cortex and the dorsal striatum (Hernandez-Echeagaray et al., 2025). CGA also alleviates memory impairment induced by scopolamine by the increase of BDNF levels in mice (Mosalam et al., 2025). Therefore, CGA may interfere with the pathophysiology of schizophrenia and may alter the function of BDNF, although evidence is so limited. The present study explored the possible effects of CGA on cognitive and behavioral alterations in a ketamine-induced schizophrenia-like rat model in both sexes, with particular attention to prefrontal BDNF expression. Materials and methods Rats Fifty-six Wistar rats [female (n = 28) and male (n = 28)] weighing 170–180 g and aged 6–7 weeks were born and bred at the Cognitive Neuroscience Lab, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran. Rats were housed seven per large Plexiglas cage (n = 7 per group) under standard laboratory conditions (12:12 h light/dark cycle, 22 +/- 1 °C), with ad libitum access to food and water. All experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Research Council Committee for the Update of the Guide for the C, Use of Laboratory A, 2011) and were approved by the institutional ethics committee. Drug administrations Ketamine hydrochloride was administered intraperitoneally at 30 mg/kg for 7 consecutive days, consistent with established ketamine-induced schizophrenia-like protocols in rodents (Faizi et al., 2014, Lisek et al., 2017, Estaphan et al., 2021). CGA was prepared at the Institute of Medicinal Plants and orally administered once at 150 mg/kg, 24 h after the last ketamine or saline injection (Singh et al., 2025, Wang et al., 2025). CGA was dissolved in DMSO and freshly prepared before oral gavage. One hour after CGA gavage, the first behavioral test (open field test) was performed. Because independent DMSO-only vehicle-control cohorts were not included in the original design, the possible contribution of vehicle-related effects is acknowledged as a limitation of the study. Open field test Locomotor activity, center-zone behavior, and grooming were recorded using the open field test. The open field consisted of a clear Plexiglas box (50 ×50 x 50 cm) divided into 16 equal squares. Locomotor activity was assessed by counting the number of squares crossed by each animal, and center-zone behavior was assessed by recording the duration spent in the central squares (Houshyar et al., 2024, Kamaei et al., 2023). Grooming behavior, defined as a sequence of movements directed toward cleaning and maintaining the fur, was also recorded as a compulsive-like behavioral measure (Brownstien et al., 2024, Hosseini et al., 2025, Zike et al., 2017). This test was conducted between 09:00 and 10:00. Marble burying test Compulsive-like behavior was also assessed using the marble burying test. Each rat was placed in a Plexiglas cage containing 10 marbles (15 mm in diameter and 5–6 g in weight) arranged in two rows of five on the bedding surface. The number of marbles buried after 30 min was recorded (Payamani et al., 2025, Abbasi et al., 2024). This test was conducted after the open field test, with an interval between behavioral testing sessions. Novel object recognition memory The novel object recognition test (NORT) included familiarization, sample, and test phases. First, each rat was allowed to explore an empty Plexiglas arena (45 ×45 x 45 cm) for 10 min. One hour later, a 10-min sample phase was performed, during which two identical objects were placed on opposite sides of the arena. After 24 h, a 10-min test phase was conducted, in which one familiar object was replaced by a novel object. The familiar and novel objects differed in shape, color, and texture (Samizadeh et al., 2024, Manooki et al., 2025, Garcia-Partida et al., 2022, Gholami-Zanjanbar et al., 2024). Recognition memory was calculated using the discrimination index (DI): (time exploring the novel object - time exploring the familiar object) / (time exploring the novel object + time exploring the familiar object) (Romero-Miguel et al., 2023). Forced swim test (FST) Immobility in the forced swim test (FST) was recorded as a passive coping/depressive-like behavioral endpoint, while recognizing that FST immobility alone does not represent a complete depressive phenotype. The FST apparatus was a transparent cylindrical container (height 50 cm, diameter 20 cm) filled two-thirds with water (20–22 °C). Each rat was placed in the water for 5 min, and the duration of immobility was recorded. The FST was performed after completion of the NORT test session (Rahimi-Danesh et al., 2023). Real-time PCR Immediately after behavioral testing, a subset of animals selected for molecular analysis (n = 3 per group; total n = 24) was deeply anesthetized with ketamine (80 mg/kg, i.p.) combined with xylazine (10 mg/kg, i.p.). After confirmation of deep anesthesia and loss of reflexes, animals were euthanized by decapitation. The prefrontal cortex was rapidly dissected and transferred to liquid nitrogen within less than 2 min (Talaee et al., 2024). Samples were stored at −80 °C until analysis. For molecular analyses, prefrontal cortex samples from three rats per group were evaluated. GAPDH was used as the housekeeping gene to normalize BDNF expression. All samples were loaded in duplicate, and the mean value was used for further analysis. The specificity of PCR products was verified by a single peak in melting-curve analysis. The primers used for real-time PCR were as follows: GAPDH: forward, 5′-AGGTCGGTGTGAACGGATTTG−3′; reverse, 5′-TGTAGACCATGTAGTTGAGGTCA−3′. BDNF: forward, 5′-GTCCCTTCTACACTTTACCTCT−3′; reverse, 5′-TCTTTCACCCTTTCCACTCC−3′. Experimental groups All the groups have been defined in this section (n = 7): Group 1 & 2 – Saline rats (males and females): saline (1 mL/rat, i.p.) was injected to the rats in 7 consecutive days. Group 3 & 4 – Ketamine (males and females): the rats received ketamine injection (30 mg/kg, i.p.) in 7 consecutive days. Group 5 & 6 – CGA (males and females): the rats received CGA administration (150 mg/kg, p.o.), once, 24 h after the last administration of saline. Group 7 & 8 – Ketamine + CGA (males and females): the rats received ketamine injection (30 mg/kg, i.p.) in 7 consecutive days and CGA administration (150 mg/kg, p.o.), once, 24 h after the last administration of ketamine. Data were analyzed using SPSS software (version 30). Behavioral outcomes were analyzed by two-way ANOVA with treatment group (saline, ketamine, CGA, and ketamine + CGA) and sex (male and female) as factors, followed by Tukey's post hoc test when appropriate. BDNF expression was analyzed using the same factorial structure in the subset selected for molecular analysis. Because independent DMSO-only vehicle-control cohorts were not included in the original design, vehicle effects could not be modeled as a separate factor. Data are expressed as mean + /- SD. P < 0.05 was considered statistically significant. Results Squares passed by each rat Two-way ANOVA showed significant effects of treatment (F3,48 = 166.24, P < 0.001), sex (F1,48 = 34.80, P < 0.001), and treatment x sex interaction (F3,48 = 13.29, P < 0.001). Tukey's post hoc test showed that ketamine increased locomotor activity in both males and females compared with the corresponding saline groups (P < 0.001), with a greater effect in females than in males (P < 0.001). CGA partially reduced ketamine-induced hyperlocomotion in males (P < 0.01 versus ketamine) but did not normalize locomotor activity in both sexes (Fig. 1). Number of squares crossed in the open field test as an index of locomotor activity in male and female rats. Data are presented as mean + /- SD, with individual data points representing values from individual animals. + + + P < 0.001 compared with the corresponding saline group; ^^P < 0.01 compared with the corresponding ketamine group; ###P < 0.001 compared with the corresponding male group; n = 7 per group. Rearing Two-way ANOVA showed significant effects of treatment (F3,48 = 3.50, P < 0.05), sex (F1,48 = 35.91, P < 0.001), and treatment x sex interaction (F3,48 = 10.55, P < 0.001). Tukey's post hoc test showed that rearing was reduced in ketamine-treated males compared with male saline controls (P < 0.001), whereas CGA did not significantly reverse this effect (Fig. 2). Number of rearing behaviors in male and female rats. Data are presented as mean + /- SD, with individual data points representing values from individual animals. + + + P < 0.001 compared with the corresponding saline group; ###P < 0.001 compared with the corresponding male group; n = 7 per group. Grooming Two-way ANOVA showed a significant effect of treatment (F3,48 = 15.29, P < 0.001) and treatment x sex interaction (F3,48 = 5.24, P < 0.01), while the main effect of sex was not significant (F1,48 = 0.66, P > 0.05). Tukey's post hoc test showed that ketamine increased grooming duration in both males and females compared with the corresponding saline groups (P < 0.001). CGA attenuated this effect in females (P < 0.001 versus ketamine) but not in males (Fig. 3). Duration of grooming behavior in male and female rats. Data are presented as mean + /- SD, with individual data points representing values from individual animals. + + + P < 0.001 compared with the corresponding saline group; ^^^P < 0.001 compared with the corresponding ketamine group; ###P < 0.001 compared with the corresponding male group; n = 7 per group. Marbles buried Two-way ANOVA showed no significant effects of treatment (F3,48 = 0.31, P > 0.05), sex (F1,48 = 0.31, P > 0.05), or treatment x sex interaction (F3,48 = 0.31, P > 0.05) on the number of buried marbles (Fig. 4). Number of buried marbles in male and female rats. Data are presented as mean + /- SD, with individual data points representing values from individual animals; n = 7 per group. Novel object recognition memory Two-way ANOVA showed a significant effect of treatment (F3,48 = 532.58, P < 0.001), while the main effect of sex (F1,48 = 0.64, P > 0.05) and treatment x sex interaction (F3,48 = 0.50, P > 0.05) were not significant. Tukey's post hoc test showed that ketamine impaired novel object recognition memory in both males and females compared with the corresponding saline groups (P < 0.001). CGA attenuated this impairment in both sexes (P < 0.001 versus ketamine); however, because locomotor activity remained altered in some ketamine + CGA groups and the archived working dataset retained the discrimination index values used for analysis but not the underlying object-specific exploration-time variables as separate fields, the NORT findings should be interpreted cautiously (Fig. 5). Discrimination index in the novel object recognition test in male and female rats. Data are presented as mean + /- SD, with individual data points representing values from individual animals. + + + P < 0.001 and + + P < 0.01 compared with the corresponding saline group; ^^^P < 0.001 compared with the corresponding ketamine group; n = 7 per group. Immobility Two-way ANOVA showed a significant effect of treatment (F3,48 = 13.82, P < 0.001) and treatment x sex interaction (F3,48 = 2.89, P < 0.05), while the main effect of sex was not significant (F1,48 = 1.77, P > 0.05). Tukey's post hoc test showed that immobility was reduced in ketamine-treated females compared with female saline controls (P < 0.001). CGA attenuated this effect in females (P < 0.001 versus ketamine) (Fig. 6). Duration of immobility in the forced swim test in male and female rats. Data are presented as mean + /- SD, with individual data points representing values from individual animals. + + + P < 0.001 compared with the corresponding saline group; ^^^P < 0.001 compared with the corresponding ketamine group; ###P < 0.001 compared with the corresponding male group; n = 7 per group. BDNF expression levels in the prefrontal cortex Two-way ANOVA showed a significant effect of treatment (F3,16 = 212.02, P < 0.001), while the main effect of sex (F1,16 = 3.74, P > 0.05) and treatment x sex interaction (F3,16 = 1.29, P > 0.05) were not significant. Tukey's post hoc test showed that prefrontal BDNF expression was decreased in ketamine-treated males and females compared with the corresponding saline groups (P < 0.001). CGA partially attenuated ketamine-induced BDNF downregulation in both sexes (P < 0.001 versus ketamine) (Fig. 7). BDNF expression levels in the prefrontal cortex of male and female rats. Data are presented as mean + /- SD, with individual data points representing values from individual animals. + + + P < 0.001 compared with the corresponding saline group; ^^^P < 0.001 compared with the corresponding ketamine group; n = 3 per group. Discussion The present study showed that sub-chronic ketamine administration increased locomotor activity in both sexes, with a greater effect in females, and that CGA partially attenuated this effect only in males. Rearing was decreased only in ketamine-treated males and was not reversed by CGA. Grooming was increased in both sexes after ketamine administration, whereas CGA attenuated this effect only in females. Novel object recognition memory was impaired by ketamine administration in both sexes, and CGA partially attenuated this impairment. FST immobility was decreased only in ketamine-treated females, and CGA attenuated this change. Prefrontal BDNF expression was decreased after ketamine administration in both sexes, and CGA partially attenuated this reduction. Overall, these findings suggest partial, task-dependent, and sex-dependent protective effects of CGA against selected behavioral and molecular alterations induced by sub-chronic ketamine administration. There are many preclinical models that mimic a human state of psychopathology associated with schizophrenia, such as psychotropic drug-induced motor hyperactivity and prepulse inhibition (Becker et al., 2003, van den Buuse et al., 2005). It has been declared that a rodent model using ketamine is widely accepted as a preclinical model of schizophrenia. Ketamine is a dissociative anesthetic agent that significantly affects glutamatergic function by blocking the N-methyl-D-aspartate (NMDA) receptors (Ellison, 1995). Therefore, administration of ketamine for 5–8 consecutive days has been considered as an approved rodent model of schizophrenia. Previous reports have shown a wide range of behavioral disturbances following sub-chronic administration of ketamine similar to schizophrenia. For example, it has been shown that repeated administration of ketamine in rats leads to changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS, similar to those found in patients with schizophrenia (Keilhoff et al., 2004). It has been revealed that sub-chronic injection of ketamine leads to hyperactivity, decreased anxiety-like behavior, and disrupted novel object memory performance in Wistar rats (Samizadeh et al., 2024, Manooki et al., 2025). Male and female rats exposed to sub-chronic administration of ketamine show hyperlocomotion and novel object memory impairment (Prado et al., 2025). In addition, maternal immune activation model in rats (schizophrenia-like model) also leads to hyperlocomotion (Meighan et al., 2021). There are many reports in this regard; however, potential sex differences have been also found. For example, a previous study has reported that females received sub-chronic administration of ketamine show greater hyperlocomotion and long-term novel object memory impairment, while males exhibit reduced sucrose preference and short-term novel object memory impairment (Prado et al., 2025). It has been shown that females exposed to sub-chronic administration of ketamine show a greater increase in locomotor activity and decrease in pain threshold (Samizadeh et al., 2024). It should be noted that impaired memory performance is the most behavioral deficit found in rodent model of schizophrenia. Many studies have shown that sub-chronic administration of ketamine potently disrupts memory performance, especially impairs novel object recognition memory in rats and mice (Samizadeh et al., 2024, Manooki et al., 2025, Tekin et al., 2022, Moghaddam et al., 2023, Moghaddam et al., 2021). The present research also showed impaired novel object recognition memory in both sexes of rats received ketamine. However, changes in rearing and grooming behaviors are controversial. Our two recent studies have shown inconsistent results. One study has shown increased rearing behavior only in males received ketamine for 5 days (Samizadeh et al., 2024), and another study has shown decreased rearing in both sexes received ketamine for 5 days (Manooki et al., 2025). It has also been shown that ketamine administration for 10 days in rats leads to decreased rearing behavior in the open field test (de Almeida Queiroz et al., 2025). But other study has shown significant increases in rearing and grooming following 10-day ketamine administration in a rat model of schizophrenia (Azimi Sanavi et al., 2022). Controversially, it has been declared that single ketamine administration increases horizontal activity and decreases rearing and grooming behaviors in both sexes of rats (Radford et al., 2020). Low doses (1.25 and 2.5 mg/kg) of acute ketamine also significantly increase anxiety-like behavior and grooming in rats (Guevara et al., 2025). In mice, ketamine administration for 14 days increases the grooming time in the nose region (Rodrigues et al., 2023). Other study has shown that ketamine administration in mice increases spontaneous locomotor activity and grooming behavior (Dias et al., 2019). Ketamine administration for 14 days also increases rearing behavior in mice (Rodrigues et al., 2025). It can be suggested that increased locomotor activity is a reliable behavioral alteration in rodent models of schizophrenia induced by ketamine; however, rearing and grooming behaviors show controversial alterations. It should be noted that the duration of ketamine administration and the time interval between the injection and the tests can affect the results of the behavioral tests. Of note, potential sex differences have not been well studied. The present study showed hyperlocomotion in both sexes with greater effect in females, increased grooming in both sexes, and decreased rearing only in males. Changes in FST immobility after ketamine administration are inconsistent across studies. A recent study reported decreased FST immobility in females exposed to 5-day ketamine administration 3 h after the last injection (Manooki et al., 2025), whereas another study showed increased immobility after 5-day ketamine administration 24 h after the last injection (Chindo et al., 2012). Increased immobility has also been reported in male BALB/c mice following ketamine administration (Mafikandi et al., 2025, Aziziha et al., 2025). A previous study suggested that chronic ketamine administration increased immobility in the FST, whereas the same effect was not observed in the tail suspension test (Chatterjee et al., 2012). Because FST immobility is influenced by methodological variables and does not alone represent a complete depressive-like syndrome, interpretation of this endpoint in ketamine-based schizophrenia models should remain cautious (Neves et al., 2017). In the present study, persistent locomotor changes, particularly in females, may also have influenced FST performance. As mentioned, BDNF (the most important neurotrophic factor in the nervous system) is highly involved in the pathophysiology of neuropsychiatric disorders including schizophrenia. In the adult brain, BDNF is crucial for neuroplasticity, apoptosis, function of neurotransmitters, and survival of various neurotransmitters networks and neurons, involved in memory and cognitive alterations in schizophrenia (Goren, 2016). It has been shown that altered function of BDNF can lead to alterations in neuronal cell development and synaptic plasticity, leading to important changes in neurotransmission that are implicated in higher cognitive functions usually disrupted in schizophrenia (Goren, 2016, Toll and Mane, 2015). It has been noted that reduced levels of BDNF negatively alter synaptic efficiency and connectivity, leading to changes in neurotransmission and the induction of symptoms consistent with schizophrenia (van Haren et al., 2008, Snigdha et al., 2011). Early life changes in BDNF are related to impaired neurotransmission and psychotic symptoms later in life (Goren, 2016). Decreased BDNF levels in the prefrontal cortex of schizophrenia patients have been shown compared with controls (Weickert et al., 2003). Also, inconsistent changes in peripheral BDNF levels have been reported in previous studies (Goren, 2016, Durany and Thome, 2004, Fernandes et al., 2015). In preclinical models, ketamine-induced BDNF changes have been widely explored. Previous study has shown that ketamine administration reduces BDNF levels in hippocampus, cortex and striata of mice (Khalid et al., 2024). Ketamine administration also reduces BDNF levels in the striatum, prefrontal cortex and hippocampus of mice (Ben-Azu et al., 2023). In both sexes of rats, sub-chronic ketamine administration significantly decreases BDNF levels in the prefrontal cortex (Samizadeh et al., 2024, Manooki et al., 2025). Of note, our recent systematic review has reported that sub-chronic and chronic ketamine treatments in rats reduce BDNF or have no effect on BDNF, while sub-chronic and chronic ketamine treatments in mice only reduce BDNF. Also, increased BDNF has been commonly observed following acute ketamine treatments (Motamedi-Manesh et al., 2025b). The results of the current research revealed that sub-chronic ketamine administrations potently reduced BDNF levels in the prefrontal cortex of male and female rats. The present study suggests that CGA may partially attenuate selected behavioral changes induced by ketamine, potentially in parallel with partial attenuation of prefrontal BDNF downregulation. CGA is an abundant dietary phenolic acid with reported anti-inflammatory, antioxidative, and metabolic effects (Nguyen et al., 2024, Xue et al., 2023, Stalmach et al., 2010). CGA has been shown to exert antioxidant and antiapoptotic effects, improve cognitive deficits, and modulate mood-related behaviors in experimental models (Bouayed et al., 2007, Han et al., 2010, Miyazaki et al., 2020). CGA may also improve learning and memory through neuroprotective pathways (Kumar et al., 2019, Tajik et al., 2017). Previous studies have reported that CGA can increase BDNF availability in the frontal cortex and dorsal striatum (Hernandez-Echeagaray et al., 2025) and attenuate scopolamine-induced memory impairment through modulation of the cAMP/PKA-CREB-BDNF pathway (Mosalam et al., 2025). Further evidence suggests that CGA can improve chronic unpredictable mild stress-induced depressive-like behaviors and upregulate hippocampal BDNF/p-TrkB signaling (Qin et al., 2023). CGA has also shown neuroprotective effects in a sporadic Alzheimer's disease model, including preservation of viable cell count and prevention of BDNF depletion in the prefrontal cortex and hippocampus (Bezerra et al., 2025). Evidence in schizophrenia-related models remains limited. Although CGA has been reported to suppress glutamate dehydrogenase activity, which may be relevant to schizophrenia pathophysiology (Domith et al., 2018), this mechanism was not directly tested in the present study. Therefore, the current findings should be interpreted as evidence that CGA partially attenuated selected ketamine-induced behavioral and BDNF-related changes, rather than as proof of a definitive antipsychotic mechanism. Limitations. The present study has several limitations that should be considered when interpreting the findings. First, separate DMSO-only vehicle-control cohorts matched to CGA administration were not included; therefore, CGA-related effects cannot be fully separated from nonspecific effects related to the vehicle and/or gavage procedure. Second, although the discrimination index derived from test-session object exploration was available and is shown with individual animal-level data points, the archived dataset did not retain the underlying object-specific raw exploration-time variables for the familiar and novel objects as separate fields; therefore, possible object-exploration bias and locomotor confounding cannot be completely excluded. Third, molecular analyses were limited to BDNF mRNA expression in a subset of prefrontal cortex samples; BDNF protein levels and downstream signaling pathways were not evaluated. Conclusion In conclusion, CGA showed partial and sex-dependent protective effects against selected behavioral and molecular alterations induced by sub-chronic ketamine administration in rats. CGA attenuated novel object recognition memory impairment and partially restored prefrontal BDNF expression in both sexes, while its effects on locomotion, grooming, and FST immobility were sex- and task-specific. These findings support further investigation of CGA as a potential adjunctive neuroprotective compound in schizophrenia-related preclinical models, but stronger conclusions require vehicle-controlled designs and additional behavioral and molecular validation. CRediT authorship contribution statement Batool Ghorbani Yekta: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Conceptualization. Anita Baghdasarians: Writing – review & editing, Writing – original draft, Methodology. Anahita Bahrami: Writing – review & editing. Consent to participate Not applicable. Consent to publish Not applicable. Ethical approval The study protocol was approved by the Islamic Azad University Ethics Committee (IR.IAU.CTB.REC.1404.158). All procedures were carried out in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (2011) and in accordance with ARRIVE guidelines. Humane endpoints were used to minimize suffering, and anesthesia/euthanasia procedures were applied according to the institutional animal welfare protocol. Animal welfare statement All efforts were made to minimize animal suffering and to reduce the number of animals used. Rats selected for molecular analysis were deeply anesthetized with ketamine/xylazine. After confirmation of deep anesthesia and loss of reflexes, euthanasia was performed by decapitation. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Declaration of Competing Interest The authors declare that they have no competing interests. Contributor Information Anahita Bahrami, Email: anahitabahrami98@gmail.com. Batool Ghorbani Yekta, Email: yekta@iautmu.ac.ir, bahareh59gh@iau.ac.ir. Anita Baghdasarians, Email: sarians72@gmail.com. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.